What IGF-1 LR3 and DES IGF-1 are
IGF-1 LR3 and DES IGF-1 are both synthetic analogues of insulin-like growth factor 1 built to solve the same problem from opposite directions. Native IGF-1 is absorbed almost immediately by IGF-binding proteins (IGFBPs) in serum and tissue, leaving only a small fraction free to reach the IGF-1 receptor. Each analogue reduces that binding, but the structural route differs, and so does the resulting research profile. Both are supplied as research compounds for laboratory use only.
IGF-1 LR3, or Long R3 IGF-1, adds a 13-amino-acid extension to the N-terminus of native IGF-1 and replaces the glutamic acid at position 3 with arginine, producing an 83-amino-acid molecule. DES IGF-1, written des(1-3)IGF-1 in the literature, does the reverse: it removes the first 3 amino acids (Gly-Pro-Glu) from native IGF-1's 70-residue chain, leaving a 67-residue peptide. DES(1-3)IGF-1 was not engineered first and characterized later, the way LR3 was. It was isolated directly from bovine colostrum, human brain tissue, and porcine uterus, and its truncated structure was worked out afterward (Sara et al., Proc Natl Acad Sci USA 1986, PMID 3460078).
How each analogue evades IGFBP binding
The N-terminal tripeptide that DES IGF-1 lacks, and that LR3 leaves untouched but buries under its 13-residue extension, is where most IGFBP contacts occur. Removing it or blocking access to it both lower affinity for IGFBPs, but not by the same amount. Reviews of the analogue place LR3's IGFBP affinity at roughly 1,000-fold below native IGF-1. DES IGF-1's reduction is smaller, commonly cited as an order of magnitude below native IGF-1's IGFBP affinity, not three orders of magnitude.
Despite that smaller reduction, DES IGF-1's biological potency in cell assays comes out close to LR3's. A 1987 bioassay by Ballard FJ and colleagues found the des-tripeptide form of IGF-1 was approximately 7 times more potent than native IGF-1 in stimulating protein synthesis, and that the extra potency did not come from tighter IGF-1 receptor binding on muscle cells (Ballard et al., Biochem Biophys Res Commun 1987, PMID 2962574). A follow-up review by the same group put the figure at up to 10-fold in later assays (Ballard et al., Int J Biochem Cell Biol 1996, PMID 8930132). In both papers, the mechanism is the same one that makes LR3 potent: more of the administered peptide stays free in solution instead of getting mopped up by IGFBPs, so more of it reaches the receptor at a given nominal dose.
Potency ranking in a direct comparison
One study put both analogues, plus a third variant, side by side in the same cell system. Francis GL and colleagues tested native IGF-1, Long IGF-1, Long [Gly3]-IGF-1, Long [Arg3]-IGF-1 (the LR3 configuration), and des(1-3)IGF-1 in cell lines that secrete their own IGFBPs into the culture medium. The ranked order of biological potency was Long [Arg3]-IGF-1 and des(1-3)IGF-1 highest, ahead of Long [Gly3]-IGF-1, which in turn outperformed both Long IGF-1 and native IGF-1 (Francis et al., J Mol Endocrinol 1992, PMID 1378742). In a system where endogenous IGFBP secretion is actively working against the added peptide, the two most IGFBP-resistant analogues in the study, despite reaching that resistance by different structural means, land in the same tier.
Where the two diverge is receptor engagement outside of IGFBP competition. LR3 binds the IGF-1 receptor at close to native affinity; its advantage is entirely about the free fraction available in serum. DES IGF-1's receptor affinity has been reported as somewhat higher than native IGF-1's in some assays, on top of its reduced IGFBP binding, which is part of why its potency multiplier holds up even though its IGFBP evasion is less extreme than LR3's.
Clearance and half-life: the tradeoff
Reduced IGFBP binding cuts both ways. IGFBP complexes protect IGF-1 from rapid degradation and filtration; an analogue that avoids them is also more exposed to clearance. A rat study by Gillespie CM and colleagues measured plasma clearance of native IGF-1, des(1-3)IGF-I, and LR3 IGF-I directly against each other, in both healthy animals and a chronic renal failure model (Gillespie et al., Am J Physiol 1996, PMID 8897852).
Total clearance of LR3 IGF-I was significantly increased relative to native IGF-1, and the same reduced-IGFBP-binding mechanism was implicated in how des(1-3)IGF-I was handled. Both analogues clear faster than the native hormone; neither one keeps the 12 to 16-hour circulating half-life that the 150-kDa IGFBP-3/ALS ternary complex gives native IGF-1.
The practical difference in research design is where that clearance happens. LR3's evasion of IGFBPs is close to total, so its effective action, once dosed, plays out mostly through direct receptor engagement over the study period, which is why it dominates multi-day cell culture and bioreactor work where a stable free-peptide concentration matters. DES IGF-1's partial IGFBP evasion and faster clearance make it better suited to studies of acute, localized signaling, which is consistent with its use in short-duration in vivo work. One example is a study of streptozotocin-diabetic rats, where des(1-3)IGF-1 treatment normalized IGF-1 receptor and phospho-Akt (Thr 308) immunoreactivity in the predegenerative retina despite ongoing hyperglycemia (Kummer et al., Int J Exp Diabesity Res 2003, PMC2480499).
Head-to-head: key differences at a glance
| Feature | IGF-1 LR3 | DES IGF-1 |
|---|---|---|
| Amino acid length | 83 (13-residue N-terminal extension plus Arg3 substitution) | 67 (Gly-Pro-Glu removed from the N-terminus) |
| Origin | Engineered fusion protein, 1990s | Isolated from bovine colostrum, human brain, and porcine uterus before synthesis |
| IGFBP affinity vs native IGF-1 | Roughly 1,000-fold lower | Roughly 10-fold lower |
| Potency vs native IGF-1 in IGFBP-secreting cells | Top tier, alongside des(1-3)IGF-1 | Top tier, alongside LR3 |
| Plasma clearance | Significantly faster than native IGF-1 | Faster than native IGF-1; mechanism linked to IGFBP evasion |
| Typical research use | Serum-free cell culture, multi-day bioreactor runs, muscle signaling studies | Short-duration in vivo dosing, acute local signaling studies |
| Human trial data | None (not tested in humans) | None (not tested in humans) |
Which analogue fits which experimental design
Neither analogue has approved human use or a listing on ClinicalTrials.gov as a tested investigational drug. Every data point above comes from cell culture models and animal studies. Where recombinant human IGF-1 does have approval, as mecasermin (Increlex, for severe primary IGF-1 deficiency), the trials used native IGF-1, not either analogue.
For serum-containing or serum-free cell culture that runs multiple days, LR3's near-total IGFBP evasion gives a more stable free-peptide concentration over time, which is why it is the default choice in CHO and HEK293 media-supplement studies. For short in vivo protocols, or designs that specifically want the smaller, faster-clearing molecule, des(1-3)IGF-1's published record covers a narrower but still real set of applications: gut and muscle anabolism in early rodent work, and the retinal signaling study above.
Handling and storage for research use
Both analogues are supplied lyophilized and share the same storage and reconstitution constraints as other research peptides. Store lyophilized stock at minus 20 degrees C or below, in a desiccated container, away from light. Indonesia's ambient humidity makes desiccant packaging non-optional rather than a nicety; the lyophilized peptide storage guide covers the specific failure modes that tropical shipping and storage introduce.
Reconstitute using sterile acidic buffer (commonly 10 mM acetic acid) or a dilute carrier protein solution rather than plain bacteriostatic water; the acidic vehicle reduces aggregation for both analogues. Aliquot immediately after reconstitution to avoid repeated freeze-thaw cycles, and use the dosing calculator to work out nanogram- and microgram-scale concentrations correctly before diluting from stock. Errors compound quickly at the concentrations typically used in published cell culture protocols for either compound.